Qiong Shou

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants.

Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants.

Journal: Human vaccines & immunotherapeutics

Published: July 17, 2025

A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China.

A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China.

Journal: Human vaccines & immunotherapeutics

Published: March 21, 2024

Application of estimand framework in ICH E9 (R1) to vaccine trials.

Application of estimand framework in ICH E9 (R1) to vaccine trials.

Journal: Journal of biopharmaceutical statistics

Published: April 04, 2023

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study.

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study.

Journal: Blood advances

Published: May 09, 2022

Semiparametric additive time-varying coefficients model for longitudinal data with censored time origin.

Semiparametric additive time-varying coefficients model for longitudinal data with censored time origin.

Journal: Biometrics

Published: October 27, 2020

Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study.

Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study.

Journal: Vaccine

Published: July 30, 2020

Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up.

Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up.

Journal: Vaccine

Published: August 08, 2018

Immunogenicity of pentavalent rotavirus vaccine in Chinese infants.

Immunogenicity of pentavalent rotavirus vaccine in Chinese infants.

Journal: Vaccine

Published: June 15, 2018

Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up.

Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up.

Journal: Vaccine

Published: January 18, 2018

Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.

Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.

Journal: Vaccine

Published: June 02, 2017

Analysis of two-phase sampling data with semiparametric additive hazards models.

Analysis of two-phase sampling data with semiparametric additive hazards models.

Journal: Lifetime data analysis

Published: May 21, 2015

Long-term study of a quadrivalent human papillomavirus vaccine.

Long-term study of a quadrivalent human papillomavirus vaccine.

Journal: Pediatrics

Published: August 20, 2014

Showing 1-12 of 12

Last Updated: 09/26/2026